Accelerate Diagnostics Overview
Valuation check: AXDX's ROE is 89.3%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow89.30%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, AXDX shows a ROE of 89.3%. That is above the Healthcare sector average of 22.01%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.01%. Accelerate Diagnostics is at 89.3%, which is higher that average. That is roughly 305.7% above the sector mean. Use the comparison chart on this page to see how AXDX stacks up against individual peers as well.
Check the historical chart to see whether AXDX's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Accelerate Diagnostics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Accelerate Diagnostics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 89.3%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.01%, while AXDX is at 89.3%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
